Alembic Pharma Q1 Results: Net profit rises 15%, revenue up 10%

Its Earnings Before Interest, Taxes, Depreciation, and Amortisation (EBITDA) grew by 19% to ₹282 crore, from ₹237 crore in the corresponding quarter last year. EBITDA margin improved to 16.5% from 15.2% on a year-on-year basis.

Leave a Reply

Your email address will not be published. Required fields are marked *